158 related articles for article (PubMed ID: 20111968)
1. Restoration of peripheral blood T cell repertoire complexity during remission in advanced cutaneous T cell lymphoma.
Yamanaka K; Fuhlbrigge RC; Mizutani H; Kupper TS
Arch Dermatol Res; 2010 Aug; 302(6):453-9. PubMed ID: 20111968
[TBL] [Abstract][Full Text] [Related]
2. Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma.
Yawalkar N; Ferenczi K; Jones DA; Yamanaka K; Suh KY; Sadat S; Kupper TS
Blood; 2003 Dec; 102(12):4059-66. PubMed ID: 12829591
[TBL] [Abstract][Full Text] [Related]
3. High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma.
Clark RA; Shackelton JB; Watanabe R; Calarese A; Yamanaka K; Campbell JJ; Teague JE; Kuo HP; Hijnen D; Kupper TS
Blood; 2011 Feb; 117(6):1966-76. PubMed ID: 21148332
[TBL] [Abstract][Full Text] [Related]
4. Derangement of the T-cell repertoire in patients with B-cell non-Hodgkin's lymphoma.
Fozza C; Corda G; Virdis P; Contini S; Barraqueddu F; Galleu A; Isoni A; Cossu A; Dore F; Careddu MG; Bonfigli S; Giannico B; Longinotti M
Eur J Haematol; 2015 Apr; 94(4):298-309. PubMed ID: 25040028
[TBL] [Abstract][Full Text] [Related]
5. Decreased T-cell receptor excision circles in cutaneous T-cell lymphoma.
Yamanaka K; Yawalkar N; Jones DA; Hurwitz D; Ferenczi K; Eapen S; Kupper TS
Clin Cancer Res; 2005 Aug; 11(16):5748-55. PubMed ID: 16115912
[TBL] [Abstract][Full Text] [Related]
6. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
Chin KM; Foss FM
Clin Lymphoma Myeloma; 2006 Nov; 7(3):199-204. PubMed ID: 17229335
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous T-cell lymphoma: Biologic targets for therapy.
Choi J; Foss F
Curr Hematol Malig Rep; 2007 Oct; 2(4):272-7. PubMed ID: 20425380
[TBL] [Abstract][Full Text] [Related]
8. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Sun Y; Straus D; Acosta M; Negro-Vilar A
J Clin Oncol; 2010 Apr; 28(11):1870-7. PubMed ID: 20212249
[TBL] [Abstract][Full Text] [Related]
9. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
Duvic M
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
[TBL] [Abstract][Full Text] [Related]
10. Denileukin diftitox.
Saxon M
Clin J Oncol Nurs; 2000; 4(6):289, 293. PubMed ID: 11899329
[TBL] [Abstract][Full Text] [Related]
11. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous T cell lymphoma: translating immunobiology into therapeutic opportunities.
Berger CL; Heald P; Girardi M; Edelson RL
G Ital Dermatol Venereol; 2008 Feb; 143(1):43-54. PubMed ID: 18833050
[TBL] [Abstract][Full Text] [Related]
13. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
[TBL] [Abstract][Full Text] [Related]
14. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).
Duvic M; Kuzel TM; Olsen EA; Martin AG; Foss FM; Kim YH; Heald PW; Bacha P; Nichols J; Liepa A
Clin Lymphoma; 2002 Mar; 2(4):222-8. PubMed ID: 11970761
[TBL] [Abstract][Full Text] [Related]
15. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
16. Localization of clonal T cells to the epidermis in cutaneous T-cell lymphoma.
Fivenson DP; Hanson CA; Nickoloff BJ
J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):717-23. PubMed ID: 7929915
[TBL] [Abstract][Full Text] [Related]
17. T-cell receptor beta variable region (V beta) usage in cutaneous T-cell lymphomas (CTCL) in comparison to normal and eczematous skin.
Potoczna N; Boehncke WH; Nestle FO; Küenzlen C; Sterry W; Burg G; Dummer R
J Cutan Pathol; 1996 Aug; 23(4):298-305. PubMed ID: 8864915
[TBL] [Abstract][Full Text] [Related]
18. Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma.
Rook AH; Junkins-Hopkins JM; McGinnis KS; Wysocka M; Richardson SK; Budgin JB; Everitts S; Vittorio CC
Adv Dermatol; 2002; 18():29-43. PubMed ID: 12528401
[TBL] [Abstract][Full Text] [Related]
19. Durable complete remission of therapy-refractory, tumor-stage cutaneous T-cell lymphoma under radioimmunotherapy with electron beam irradiation and denileukin diftitox.
Wobser M; Göppner D; Lang SC; Beckmann G; Flentje M; Ugurel S; Bröcker EB; Becker JC
Arch Dermatol; 2010 Jul; 146(7):805-6. PubMed ID: 20644054
[No Abstract] [Full Text] [Related]
20. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
Zaki MH; Shane RB; Geng Y; Showe LC; Everetts SE; Presky DH; Wysocka M; Moore JS; Rook AH
J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
